ACVRL1 and breast carcinoma: Immunological sequestration of ALK1 ligands (using ALK1-Fc) or antibody against ALK1 have been reported to inhibit tumor angiogenesis and tumor growth in mouse models of pancreatic cancer, breast cancer, and melanoma (Roman and Hinck, 2017).